Global Alliance for TB Drug Development
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tballiance.org
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 74
- Registration Number
- NCT03199339
- Locations
- πΊπΈ
Worldwide Clinical Trials, San Antonio, Texas, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 32
- Registration Number
- NCT03199313
- Locations
- πΊπΈ
Worldwide Clinical Trials, San Antonio, Texas, United States
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 181
- Registration Number
- NCT03086486
- Locations
- πΏπ¦
Tshepong Hospital, Klerksdorp, North - West, South Africa
π²π©Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova, Republic of
π·πΊMoscow City Research and Practice Tuberculosis Treatment Centre, Moscow, Russian Federation
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 18
- Registration Number
- NCT02606214
Shortening Treatment by Advancing Novel Drugs
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 284
- Registration Number
- NCT02342886
- Locations
- πΉπΏ
Kilimanjaro National Institute for Medical Research, Mwanza, Tanzania
πΏπ¦TASK, Bellville, Cape Town, South Africa
πΊπ¬Uganda CWRU Research Collaboration, Kampala, Uganda
A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 109
- Registration Number
- NCT02333799
- Locations
- πΏπ¦
Task Applied Science - Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa
πΏπ¦King DinuZulu Hospital Complex, Sydenham, Durban, South Africa
πΏπ¦Sizwe Tropical Disease Hospital, Sandringham, Johannesburg, South Africa
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 48
- Registration Number
- NCT02288481
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 113
- Registration Number
- NCT02279875
- Locations
- πΏπ¦
TASK Clinical Research Centre, Bellville, Cape Town, South Africa
πΏπ¦University of Cape Town Lung Institute (Pty) Ltd, Mowbray, Cape Town, South Africa
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 32
- Registration Number
- NCT02216331
- Locations
- πΊπΈ
Celerion (MDS Pharma Services), Lincoln, Nebraska, United States
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 240
- Registration Number
- NCT02193776
- Locations
- πΏπ¦
Klerksdorp Tshepong Hospital, Jouberton, Klerksdorp, South Africa
πΏπ¦The Aurum Institute: Tembisa Hospital, Tembisa, Gauteng, South Africa
πΉπΏNIMR-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania